Adding to its manufacturing capabilities in China and Malaysia, medical device contract manufacturer Sanbor Medical is scheduled to open a new manufacturing facility in the United States by the end of 2020. With the new facility comes a new Hybrid Manufacturing Model.
“Customers have always had the option of outsourcing some or all of their medical device manufacturing, but due to the recent virus and geopolitical concerns, more and more companies are looking to add stability to their supply chain while remaining competitive with their pricing,” says Joe Pignotti, Sales Manager of Sanbor Medical.
“To help medical device OEMs meet their budgetary and profit goals, we are offering them the choice of having some, or all of their product’s manufacturing done in Asia and other parts of their manufacturing done in the United States. As a privately owned U.S. company, owning operations in both markets, we are able to operate with a single profit center. This offers savings to our customers of anywhere from 20-25% when they continue to source components and do some part of their product’s manufacturing in low-cost countries and do final packaging and assembly closer to their market. European customers marketing to the Americas can now choose to do as much or as little of the manufacturing of their product in both geographical areas, or just one, and reap the benefits of that customization.”
Quoting for 2021 projects is underway.
In business for over 30 years, Sanbor Medical is FDA registered, has passed an FDA audit with zero nonconformities, is QSR compliant and certified to ISO 13485:2016 standards.